{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceftazidime&page=2",
    "query": {
      "intervention": "Ceftazidime",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceftazidime&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T11:45:21.674Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00690378",
      "title": "Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection"
      ],
      "interventions": [
        {
          "name": "NXL104/ceftazidime",
          "type": "DRUG"
        },
        {
          "name": "Imipenem/Cilastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 137,
      "start_date": "2008-11",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690378"
    },
    {
      "nct_id": "NCT01595438",
      "title": "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Ceftazidime - Avibactam ( CAZ-AVI)",
          "type": "DRUG"
        },
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)",
          "type": "DRUG"
        },
        {
          "name": "or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 598,
      "start_date": "2012-10",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 3,
      "location_summary": "Sylmar, California • Royal Oak, Michigan • Lima, Ohio",
      "locations": [
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Lima",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01595438"
    },
    {
      "nct_id": "NCT04358991",
      "title": "Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Ceftazidime-avibactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-01-01",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2020-09-29",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04358991"
    },
    {
      "nct_id": "NCT04785924",
      "title": "Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carbapenem-Resistant Enterobacteriaceae Infection",
        "KPC",
        "Gram-Negative Bacterial Infections",
        "Antibiotic Resistant Infection"
      ],
      "interventions": [
        {
          "name": "Imipenem+Relebactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-07",
      "completion_date": "2023-01-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04785924"
    },
    {
      "nct_id": "NCT02732327",
      "title": "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Febrile Neutropenia"
      ],
      "interventions": [
        {
          "name": "CAZ-AVI",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-05-17",
      "completion_date": "2016-06-27",
      "has_results": true,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02732327"
    },
    {
      "nct_id": "NCT00035425",
      "title": "Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Febrile Neutropenia"
      ],
      "interventions": [
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2001-11",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2009-12-01",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035425"
    },
    {
      "nct_id": "NCT00195923",
      "title": "Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Perforated Appendicitis"
      ],
      "interventions": [
        {
          "name": "Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Mercy Hospital Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Month to 18 Years"
      },
      "enrollment_count": 100,
      "start_date": "2005-04",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2007-04-06",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195923"
    },
    {
      "nct_id": "NCT00707239",
      "title": "Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia, Bacterial"
      ],
      "interventions": [
        {
          "name": "tigecycline",
          "type": "DRUG"
        },
        {
          "name": "imipenem/cilastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2008-12",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-07-10",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707239"
    },
    {
      "nct_id": "NCT02099240",
      "title": "Patients Response to Early Switch To Oral:Osteomyelitis Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Osteomyelitis"
      ],
      "interventions": [
        {
          "name": "oral antibiotics",
          "type": "DRUG"
        },
        {
          "name": "intravenous antibiotics",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Julio Ramirez",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 11,
      "start_date": "2014-03-06",
      "completion_date": "2018-11-07",
      "has_results": false,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02099240"
    },
    {
      "nct_id": "NCT06406114",
      "title": "Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug Allergy",
        "Cephalosporin Allergy",
        "Drug Hypersensitivity",
        "Antibiotic Allergy",
        "Beta Lactam Adverse Reaction",
        "Drug-Induced Anaphylaxis",
        "Cephalosporin Reaction"
      ],
      "interventions": [
        {
          "name": "Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing",
          "type": "DRUG"
        },
        {
          "name": "Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        },
        {
          "name": "Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        },
        {
          "name": "Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 300,
      "start_date": "2025-05-05",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-29T11:45:21.674Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06406114"
    }
  ]
}